ferric citrate

AssetAlso called Auryxia, ferric chloride, Fexeric

Binds dietary phosphate in the gastrointestinal tract, reducing phosphate absorption and serum phosphorus levels.

Stage
Approved
Modality
Small molecule
Target
Not known
15
Indications
21
Trials
5
Developers

Approved by the FDA on Sep 5, 2014 (NDA205874). FDA

Indications

15
  • Hyperphosphatemia in dialysis-dependent chronic kidney disease

    Approved, SEC filing

  • Iron deficiency anemia in non-dialysis-dependent chronic kidney disease

    Approved, SEC filing

  • Anemia in chronic kidney disease

    Approved, FDA

12 more

In the full profile

  • Target and mechanism1
  • Owner and partners7
  • Trials21
  • Evidence for its targets2
  • Competitors12
  • Signals9

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets